According to GlobalData’s medical device pipeline database, 29 Lyme Disease Tests devices are in various stages of development globally. GlobalData’s report Lyme Disease Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 16 are in active development, while the remaining 13 are in an inactive stage of development. There are eight products in the early stages of development, and the remaining eight are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Lyme Disease Tests are carried out to diagnose infections caused by the tick-borne bacterium Borrelia, which can result in neurological and joint disease. This segment includes Lyme Disease Enzyme Immunoassay Tests, Lyme Disease Western Blot Tests, and Lyme Disease Other Tests.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Lyme Disease Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Lyme Disease Tests devices. Overall, most of these Lyme Disease Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Lyme Disease Tests include Roche Diagnostics International, L2 Diagnostics, Massachusetts Institute of Technology, Meridian Bioscience, Northern Arizona University, Qiagen, RareCyte, Seegene, Siemens Healthineers and Steven & Alexandra Cohen Foundation.
For a complete picture of the developmental pipeline for Lyme Disease Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.